Thank you for your Generous Donation!
Your support enables the NET Research Foundation to make rapid progress toward discovering cures for carcinoid, pancreatic, and related neuroendocrine cancers. Tribute gifts can be made in honor or memory of a loved one.
NETRF Recognized as Top-Tier Charity
NETRF’s strong financial position, transparency, and accountability again earned it a 4-star rating by Charity Navigator, a national evaluator of nonprofits. The 4-star rating indicates the utmost in fiscal responsibility, ethical practices, and governance.
News & Updates
Tumor-Killing Targeted Radiation Shown to Help NET Patients Live Longer The first Peptide Receptor Radionuclide Therapy (PRRT) has received FDA approval. Lutetium 177 DOTA-TATE (Lu 177), a type of PRRT, is now approved for the treatment of somatostatin-receptor-positive gastroenteropancreatic
A world where patients are not waiting years for a diagnosis, going from doctor to doctor seeking answers. And not finding the answers they need. More and better treatments for all NET patients, so they can